Maria Makri

Genesis Pharma

GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Southeast Europe. GENESIS Pharma SA started its activity in pharmaceutical biotechnology in 1997, at a time when biopharmaceutical industry was still at an early development stage in Europe. The company's goal was to combine the rapid progress in science with a successful and innovative business venture, thus paving the way for the creation of a new market. Working with consistency and dedication to this end, GENESIS Pharma SA became the first greek pharmaceutical company specializing in the commercialization of innovative biopharmaceutical products. Today, the company ranks among the largest pharmaceutical companies operating in the greek market by turnover. In 1999, business activities were expanded in Cyprus through the creation of Genesis Pharma (Cyprus) Ltd, and later on, in markets of Southeast Europe. GENESIS Pharma (Cyprus) Ltd, an affiliate (sister) company, is now operating across the region through its subsidiaries in Bulgaria, Romania, Croatia, Slovenia, Serbia, and North Macedonia. (www.genesispharmagroup.com) GENESIS Pharma has established long-term alliances with leading global biopharma companies and is responsible for a unique portfolio which includes innovative biopharmaceuticals that tackle severe and rare diseases. Its novel branded pharmaceutical products cover the therapeutic areas of Haematology, Oncology, Central Nervous System, Nephrology, Gastroenterology, Rheumatology, Dermatology as well as Rare Genetic Inherited diseases.